Recommended Dosage of Icosapent Ethyl (Vascepa) for CKD Stage 4 Patients
The recommended dosage of icosapent ethyl (Vascepa) is 4 grams per day, taken as either four 0.5-gram capsules twice daily with food or two 1-gram capsules twice daily with food, regardless of kidney function including CKD stage 4. 1
Standard Dosing Regimen
- Total daily dose: 4 grams per day administered in two divided doses with meals 1
- Dosing options:
- Four 0.5-gram capsules twice daily with food, OR
- Two 1-gram capsules twice daily with food 1
- Administration instructions: Patients must swallow capsules whole—do not break open, crush, dissolve, or chew 1
No Dose Adjustment Required for Renal Impairment
- CKD stage 4 does not require dose modification of icosapent ethyl 2
- The REDUCE-IT RENAL analysis specifically evaluated patients across the full spectrum of kidney function, including those with eGFR <60 mL/min/1.73 m² (which encompasses CKD stages 3-5), and found consistent cardiovascular benefit with the standard 4-gram daily dose 2
- No meaningful changes in median eGFR occurred with icosapent ethyl versus placebo across study visits, indicating renal safety 2
Evidence Supporting This Dosage in CKD Patients
- In the REDUCE-IT trial subgroup with eGFR <60 mL/min/1.73 m², icosapent ethyl 4 grams daily reduced the primary composite endpoint by 29% (HR 0.71,95% CI 0.59-0.85, P=0.0002) compared to placebo 2
- Patients with reduced kidney function experienced the largest absolute risk reduction for cardiovascular events, making this population particularly likely to benefit from the standard dose 2
- A post-hoc analysis of stage 3 CKD patients confirmed that icosapent ethyl 4 grams daily significantly reduced triglycerides (-16.9%, P=0.0074) and atherogenic markers without altering eGFR or serum creatinine 3
Clinical Context for This Patient Population
- This dosage applies to patients meeting REDUCE-IT criteria: established ASCVD or diabetes with ≥2 additional risk factors, triglycerides ≥150 mg/dL, and on maximally tolerated statin therapy 4, 1, 5
- The American College of Cardiology recommends adding icosapent ethyl for patients with clinical ASCVD, LDL-C <70 mg/dL on maximally tolerated statin, and persistent fasting triglycerides ≥150 and <500 mg/dL 4
Important Safety Considerations in CKD Stage 4
- Atrial fibrillation risk: While patients with eGFR <60 mL/min/1.73 m² had the highest numeric rates of atrial fibrillation/flutter (4.2% vs 3.0% placebo), the hazard ratio was similar across all eGFR categories (P-interaction=0.92) 2
- Bleeding risk: Serious bleeding occurred in 5.4% of CKD patients on icosapent ethyl versus 3.6% on placebo, but the hazard ratio was consistent across kidney function levels (P-interaction=0.76) 2
- Monitor patients receiving concomitant anticoagulants or antiplatelet agents more closely for bleeding, as this risk is increased 1
Pre-Treatment Requirements
- Assess lipid levels before initiating therapy and identify other causes of hypertriglyceridemia (diabetes, hypothyroidism, medications) 1
- Ensure patients engage in appropriate nutritional intake and physical activity before and during treatment 1
- Verify patient is on maximally tolerated statin therapy before adding icosapent ethyl 4, 1